Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
1 GROWTH
KisqaliⓇ delivers double-digit growth across regions
CEZ KISQALI K L
Sales evolution
USD m, % cc
Ex-US
US
+28% cc
239
195
160
124
71
79
Q1 2021
Q1 2022
■ CDK4/6 (TRX) market trending towards recovery to pre-COVID
levels; US growth mainly driven by adjuvant use
■ KisqaliⓇ grew 28% cc vs. PY; US growing in line with market,
Europe growing ahead of market
■ MONALEESA-2 results published in NEJM, showing ~5 years
median overall survival, longest ever reported in aBC
■ NATALEE adjuvant study primary analysis now expected 2023
In ph3 randomized controlled trials, ribociclib + endocrine therapy has shown overall survival benefit in the first-line setting.
11 Investor Relations | Q1 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation